NFAT (Luc) HEK293 Reporter Cell
描述（Description）
The NFAT (Luc) HEK293 Reporter Cell was engineered with the NFAT response element driving luciferase expressing systems. The receptors expressing endogenously or transfected on this reporter cell were activated by corresponding ligands binding, transducing intracellular signals resulting in NFAT-RE mediated luminescence.
應(yīng)用說明（Application）
1. The discovery of activators or inhibitors by the NFAT signaling bioactivity
2. Transfection host for some receptors concerning the NFAT signaling pathway
生長特性（Growth Properties）
Adherent
篩選標記（Selection Marker）
Hygromycin (50 μg/mL)
培養(yǎng)基（Culture Medium）
DMEM medium + 10% FBS
凍存液（Freeze Medium）
Serum-free cell cryopreservation medium
裝量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存儲（Storage）
Frozen in liquid nitrogen.
支原體檢測（Mycoplasma Testing）
Negative
無菌檢測（Sterility Testing）
Negative
使用說明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
Nuclear factor of activated T cells (NFAT), which is the pharmacological target of immunosuppressants cyclosporine and tacrolimus, has been shown to play an important role in T cells (immune system) and many biological events. Accumulating studies have indicated that NFATs are involved in many aspects of cancer, including carcinogenesis, cancer cell proliferation, invasion, metastasis, angiogenesis, drug resistance and tumor microenvironment. As the key section of the adaptive immune response, the T cell receptor (TCR)-calcium-calcineurin signaling pathway could lead to T cell activation. The 'nuclear factor of activated T cells' proteins are transcription factors that promote expression of a panel of genes required for activation.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
關(guān)鍵字： NFAT報告細胞系;NFAT報告細胞株;NFAT細胞系;NFAT細胞株;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。